✦ LIBER ✦

Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti–tumor necrosis factor α but not methotrexate

✍ Scribed by Katia Varani; Alfonso Massara; Fabrizio Vincenzi; Alice Tosi; Melissa Padovan; Francesco Trotta; Pier Andrea Borea

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 342 KB
Volume: 60
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.24794

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Active but transient improvement of endo

Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody

✍ Gonzalez-Juanatey, Carlos ;Testa, Ana ;Garcia-Castelo, Alberto ;Garcia-Porrua, C 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

## Abstract ## Objective Cardiovascular disease is the major cause of excessive mortality in rheumatoid arthritis (RA). Atherosclerosis and RA share similar inflammatory mechanisms that include involvement of tumor necrosis factor α (TNFα). Anti‐TNFα antibody improved endothelial function in RA pa

High levels of osteoprotegerin and solub

High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti–tumor necrosis factor α treatment

✍ Maria Ziolkowska; Mariola Kurowska; Anna Radzikowska; Grazyna Luszczykiewicz; Pi 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 1 views

## Abstract ## Objective To test the hypotheses that 1) proinflammatory cytokines affect osteoprotegerin (OPG) and soluble receptor activator of nuclear factor κB ligand (sRANKL) production and therefore the OPG and sRANKL levels differ in rheumatoid arthritis (RA) patients in comparison with heal

Radiographic, clinical, and functional o

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial

✍ Edward C. Keystone; Arthur F. Kavanaugh; John T. Sharp; Hyman Tannenbaum; Ye Hua 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 1 views

Erratum: M.E. Weinblatt, E.C. Keystone,

Erratum: M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, C.A. Birbara, L.A. Teoh, S.A. Fischkoff, and E.K. Chartash. Adalimumab, a Fully Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, for the Treatment of Rheumatoid Arthritis in Patients Taking Concomitant Methotrexate: The ARMADA Trial, Arthritis & Rheumatism (2003) 48(1) 35-45.

📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 39 KB 👁 1 views

## Abstract The original article to which this Erratum refers was published in Arthritis & Rheumatism(2003) 48(1) 35–45 In the article by Weinblatt et al published in the January 2003 issue of __Arthritis & Rheumatism__ (pp 35–45), there was an error in data reported in the first paragraph of the